OTEZLA (apremilast) tablets
OTEZLA is a prescription medicine used to treat arthritis. FDA approved tezacaftor/ivacaftor (brand name OTEZLA) is not (yet) registered or available in India but on request Indian patient can buy OTEZLA at the lowest price.
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
OTEZLA (apremilast) tablets
Apremilast, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4).
OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:
• Adult patients with active psoriatic arthritis
• Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy
• Adult patients with oral ulcers associated with Behçet’s Disease
Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4).
OTEZLA (apremilast) tablets, for oral use Initial U.S. Approval: 2014
—————-
Current Indication: Treat Adult patients with active psoriatic arthritis, Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, Adult patients with oral ulcers associated with Behçet’s Disease
—————-
Marketed By: Amgen Inc
—————-
Approval Date: : 2014
—————-
Active ingredient: apremilast
—————-
Tablets: 10 mg, 20 mg, 30 mg
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare Life Sciences Pvt. Ltd. act as facilitator for import of restricted and internationally sourced anti-cancer medicines into India. Alleviare Life Sciences is one such organization that may provide support services related to documentation, customs coordination, and temperature-controlled transportation. Patients should consult their treating physician and verify all regulatory requirements before pursuing access to any imported medicine.
Get in touch with support team of Alleviare Life Sciences Pvt. Ltd. to learn about available patient access and import facilitation options.
Contact the facilitator: Mr. Kamal
Address: Mezzanine Floor, S-9, Green Park Extension, South Delhi, Delhi, 110016
Call: @ +91-9289711087 / 9289711088
WhatsApp: @ +91-9289711087 / 9289711088
Email: info@alleviareindia.com
Website: www.alleviareindia.com
Get access to FDA approved medicines in India.
On request of patient, we have facilitated patient in import process to get delivered in time. If patients from following city in India looking for speciality medicines can contact us for the same – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.
Who facilitates the import of restricted and internationally sourced anti-cancer medicines into India?
Alleviare Life Sciences Pvt. Ltd. act as facilitator for import of restricted and internationally sourced anti-cancer medicines into India. We provides support and guidance regarding patient-specific medicine access pathways, subject to applicable regulatory requirements and healthcare provider recommendations. Contact us to learn more about the available processes and documentation requirements.If you’re considering OTEZLA, We can outline the exact documents and process typically used for a Form 12A/Form 12B application.Looking for access to overseas or restricted anti-cancer medicines in India?
We facilitates patient specific access to medicines under Named Patient Program permitted by CDSCO through Form 12B import permit.How much does OTEZLA cost in the India?
Kindly contact us to confirm the current price and availability of OTEZLA (apremilast) tablets. Product pricing is generally based on the manufacturer’s listed price and may be subject to change without notice. Additional charges, including Named Patient support fees, shipping costs, and applicable local taxes, may apply. Final pricing and availability will be confirmed at the time of inquiry.What documents are required to import OTEZLA to India?
To legally initiate the import process, you or your representative must compile the following paperwork: Valid Prescription, Form 12A Application, Medical Records, Patient Identity Proof.
How can patients in India access imported OTEZLA?
Alleviare facilitates access to patient-specific medicines through applicable regulatory pathways, including the Named Patient Program, where permitted under Indian law and subject to the necessary approvals, documentation, and import permissions issued by the relevant authorities.
How can patients access medicines that are not yet approved or registered in India?
The medicines referenced on this website may not be approved for commercial marketing or general distribution in India. Any access, where permitted, is intended solely for an individual patient pursuant to a valid prescription and under the supervision of a qualified healthcare professional.
Is OTEZLA currently available in India?
As of June 2026, OTEZLA (apremilast) tablets is not generally approved for routine marketing in India by the Indian regulator (CDSCO), based on currently available public information.
However, Indian patients may be able to access it through a Named Patient Import / Named Patient Program pathway when prescribed by an oncologist and imported for a specific patient.
Is apremilast available in India?
No, FDA approved apremilast (brand name OTEZLA) is not (yet) registered or available in India but on request Indian patient can get access.
Alleviare will help patient / doctor to get in India.
What regulatory requirements apply to accessing medicines not yet approved in India?
Personal-use / Named Patient Import (most common pathway)
For an individual patient, the primary route is import for personal use under Rule 36 of the Drugs and Cosmetics Rules, 1945. A treating physician must prescribe the medicine, and an application is made to CDSCO in Form 12A. If approved, CDSCO issues a Form 12B permit authorizing import of a limited quantity for that specific patient.
How can eligible patients explore access to inflammatory autoimmune conditions medicines not currently approved in India?
Eligible patients may discuss potential treatment options with their treating oncologist and explore available patient-specific access pathways for certain inflammatory autoimmune conditions medicines that are not currently approved or commercially available in India. Access, where applicable, is subject to physician recommendation, regulatory requirements, and relevant documentation.